Patent · US Active

Truncated von Willebrand factor polypeptides for treating hemophilia

US10688157B2 · kind B2 · utility

1Cited by

4References

23Claims

0Family size

Assignee

CSL BEHRING LENGNAU AG · CH

Inventors

Stefan Schulte · Marburg, DE
Hubert Metzner · Marburg, DE
Sabine Pestel · Biberach, DE
Thomas Weimer · Gladenbach, DE

Key dates

Filing date	May 20, 2016
Grant date	Jun 23, 2020
Priority date	—
Expiry date	May 20, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2300/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, wherein the polypeptide carries a half-life extending moiety and is administered in molar excess over Factor VIII and/or endogenous VWF.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.